Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 47Neutropenia 26Lymphoma 25Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Neoplasms 11Sarcoma 9Lymphoma, Follicular 9Ovarian Neoplasms 8Lymphoma, Mantle-Cell 8Leukemia 8Hodgkin Disease 8Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Triple Negative Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Lymphoma, B-Cell, Marginal Zone 5Chemotherapy-induced Neutropenia 5Rhabdomyosarcoma 4Neoplasm Metastasis 4Lymphoma, Large-Cell, Immunoblastic 4Burkitt Lymphoma 4Waldenstrom Macroglobulinemia 3Urinary Bladder Neoplasms 3Testicular Neoplasms 3Sarcoma, Synovial 3Prostatic Neoplasms 3Neurofibrosarcoma 3

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Recurrence × pegfilgrastim × Clear all
NCT01416389 2019-09-18

A Study of LY2523355 in Participants With Breast Cancer

Eli Lilly and Company

Phase 2 Completed
39 enrolled 16 charts
Breast

Breast Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡